pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharmaceuticals clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
Elan Pharmaceuticals projects
8 ClinicalTrials.gov programs sponsored by Elan Pharmaceuticals.
Elan Pharmaceuticals has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
General anesthesia and opioids
Elan Pharma International
Breast Neoplasms
1 trial -
HZNP-DAZ-301
Elan Pharma International
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
1 trial -
HZNP-DAZ-303
Elan Pharma International
Sjögren’s Syndrome With Moderate-toSevere Symptom State
1 trial -
Imiquimod
Elan Pharma International
Lentigo Maligna
1 trial -
OCUS-Mode-CT-V1
Elan Pharma International
Myopia
1 trial -
TMC125
Elan Pharma International
HIV-1
1 trial -
VIB0551.P3.S1
Elan Pharma International
Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
1 trial -
VIB0551.P3.S2
Elan Pharma International
Immunoglobulin G4-related disease (IgG4-RD)
1 trial
Frequently asked questions
How many clinical projects does Elan Pharmaceuticals have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.